Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study

被引：0
|
作者：
Miles, D.
Baselga, J.
Amadori, D.
Sunpaweravong, P.
Semiglazov, V.
Knott, A.
Clark, E.
Ross, G.
Swain, S. M.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[5] Prince Songkla Univ, Songklanagarind Hosp, Hat Yai, Thailand
[6] NN Petrov Res Inst Oncol, St Petersburg, Russia
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] MedStar Washington Hosp Ctr, Washington, DC USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [2] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [3] Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
    Ewer, Michael
    Baselga, Jose
    Clark, Emma
    Benyunes, Mark
    Ross, Graham
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
    Baselga, Jose
    Swain, Sandra M.
    CLINICAL BREAST CANCER, 2010, 10 (06) : 489 - 491
  • [5] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [6] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [7] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [8] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [9] Safety of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in patients (pts) from Asia with HER2-positive metastatic breast cancer (MBC): Results from the phase III trial CLEOPATRA
    Swain, S. M.
    Im, Y-H
    Im, S-A
    Miles, D.
    Knott, A.
    Clark, E.
    Ross, G.
    Baselga, J.
    CANCER RESEARCH, 2013, 73
  • [10] Distichiasis in association with entropion in metastatic HER2-positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy
    Tas, Faruk
    Ozturker, Can
    BREAST JOURNAL, 2020, 26 (05): : 1004 - 1006
12345